It was early November. The Food and Drug Administration had just endured the high-profile, dramatic exit of its top drug regulator. Personnel complaints had racked up. And other grievances within the agency that had already been rocked by layoffs and policy shifts continued to unfold.

A top economic adviser to President Donald Trump hinted at a “backup plan” if the White House loses its Supreme Court fight over tariffs.